🚀 VC round data is live in beta, check it out!
ImmunityBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for ImmunityBio and similar public comparables like Krystal Biotech, Gedeon Richter, Kyowa Kirin, PharmaEssentia and more.
ImmunityBio Overview
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Founded
2014
HQ
Employees
691
Website
Sectors
Financials (LTM)
EV
$8B
ImmunityBio Financials
ImmunityBio reported last 12-month revenue of $142M.
In the same LTM period, ImmunityBio generated $137M in gross profit and had net loss of ($323M).
Revenue (LTM)
ImmunityBio P&L
In the most recent fiscal year, ImmunityBio reported revenue of $113M and EBITDA of ($224M).
ImmunityBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $142M | XXX | $113M | XXX | XXX | XXX |
| Gross Profit | $137M | XXX | $113M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($224M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (197%) | XXX | XXX | XXX |
| EBIT Margin | (172%) | XXX | (226%) | XXX | XXX | XXX |
| Net Profit | ($323M) | XXX | ($351M) | XXX | XXX | XXX |
| Net Margin | (227%) | XXX | (310%) | XXX | XXX | XXX |
| Net Debt | — | — | $389M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ImmunityBio Stock Performance
ImmunityBio has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
ImmunityBio's stock price is $7.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | 0.0% | XXX | XXX | XXX | $-0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImmunityBio Valuation Multiples
ImmunityBio trades at 57.8x EV/Revenue multiple, and (36.7x) EV/EBITDA.
EV / Revenue (LTM)
ImmunityBio Financial Valuation Multiples
As of April 19, 2026, ImmunityBio has market cap of $8B and EV of $8B.
Equity research analysts estimate ImmunityBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ImmunityBio has a P/E ratio of (24.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 57.8x | XXX | 72.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (36.7x) | XXX | XXX | XXX |
| EV/EBIT | (33.6x) | XXX | (32.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 59.9x | XXX | 72.9x | XXX | XXX | XXX |
| P/E | (24.6x) | XXX | (22.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (26.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ImmunityBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ImmunityBio Margins & Growth Rates
ImmunityBio's revenue in the last 12 month grew by 105%.
ImmunityBio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
ImmunityBio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 105% | XXX | 85% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (197%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (15%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 109% | XXX | 132% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 157% | XXX | 193% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 325% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ImmunityBio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ImmunityBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Krystal Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Gedeon Richter | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyowa Kirin | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaEssentia | XXX | XXX | XXX | XXX | XXX | XXX |
| Halozyme Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ImmunityBio M&A Activity
ImmunityBio acquired XXX companies to date.
Last acquisition by ImmunityBio was on XXXXXXXX, XXXXX. ImmunityBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ImmunityBio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImmunityBio Investment Activity
ImmunityBio invested in XXX companies to date.
ImmunityBio made its latest investment on XXXXXXXX, XXXXX. ImmunityBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ImmunityBio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ImmunityBio
| When was ImmunityBio founded? | ImmunityBio was founded in 2014. |
| Where is ImmunityBio headquartered? | ImmunityBio is headquartered in United States. |
| How many employees does ImmunityBio have? | As of today, ImmunityBio has over 691 employees. |
| Who is the CEO of ImmunityBio? | ImmunityBio's CEO is Richard Adcock. |
| Is ImmunityBio publicly listed? | Yes, ImmunityBio is a public company listed on Nasdaq. |
| What is the stock symbol of ImmunityBio? | ImmunityBio trades under IBRX ticker. |
| When did ImmunityBio go public? | ImmunityBio went public in 2021. |
| Who are competitors of ImmunityBio? | ImmunityBio main competitors are Krystal Biotech, Gedeon Richter, Kyowa Kirin, PharmaEssentia. |
| What is the current market cap of ImmunityBio? | ImmunityBio's current market cap is $8B. |
| What is the current revenue of ImmunityBio? | ImmunityBio's last 12 months revenue is $142M. |
| What is the current revenue growth of ImmunityBio? | ImmunityBio revenue growth (NTM/LTM) is 105%. |
| What is the current EV/Revenue multiple of ImmunityBio? | Current revenue multiple of ImmunityBio is 57.8x. |
| Is ImmunityBio profitable? | No, ImmunityBio is not profitable. |
| What is the current net income of ImmunityBio? | ImmunityBio's last 12 months net income is ($323M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.